ArticleOncology letters2016
Strategies and developments of immunotherapies in osteosarcoma.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Systemic strategies for osteosarcoma: advances and future directions.Discover oncology · 2025Review
- Oncolytic Viral Therapy in Osteosarcoma.Viruses · 2024Review
- Article
- Antioxidant 1 copper chaperone gene expression and copper levels in dog osteosarcoma patients.Veterinary and comparative oncology · 2023Article
- Selenium-incorporated mesoporous silica nanoparticles for osteosarcoma therapy.Biomaterials science · 2023Article
- Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.Cancer science · 2022Article
- Radiation therapy enhances systemic antitumor efficacy in PD-L1 therapy regardless of sequence of radiation in murine osteosarcoma.PloS one · 2022Article
- circPVT1 promotes osteosarcoma glycolysis and metastasis by sponging miR-423-5p to activate Wnt5a/Ror2 signaling.Cancer science · 2021Article
- Osteosarcoma Pathogenesis Leads the Way to New Target Treatments.International journal of molecular sciences · 2021Review
- Effects of lncRNA TUSC7 on the malignant biological behavior of osteosarcoma cells via regulation of miR-375.Oncology letters · 2020Article
- The Sp1/FOXC1/HOTTIP/LATS2/YAP/β-catenin cascade promotes malignant and metastatic progression of osteosarcoma.Molecular oncology · 2020Article
- Downregulation of miR-22 Contributes to Epithelial-Mesenchymal Transition in Osteosarcoma by Targeting Twist1.Frontiers in oncology · 2020Article
- Article
- Elevated circulating macrophage inhibitory cytokine 1 is a biological marker for the diagnosis and prognosis of osteosarcoma.Experimental and therapeutic medicine · 2018Article
- miR-26a suppresses osteosarcoma migration and invasion by directly targeting HMGA1.Oncology letters · 2018Article
- miRNA-133b targets FGFR1 and presents multiple tumor suppressor activities in osteosarcoma.Cancer cell international · 2018Article
- Long non-coding RNA ZFAS1 sponges miR-486 to promote osteosarcoma cells progression and metastasisOncotarget · 2017Article
- Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.Oncotarget · 2017Review
- FOXO1-MALAT1-miR-26a-5p Feedback Loop Mediates Proliferation and Migration in Osteosarcoma Cells.Oncology research · 2017Article
- Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics.Acta veterinaria Scandinavica · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is a frequently observed primary malignant tumor. Current therapy for osteosarcoma consists of comprehensive treatment. The long-term survival rate of patients exhibiting nonmetastatic OS varies between 65-70%. However, a number of OS cases have been observed to be resistant to currently used therapies, leading to disease recurrence and lung metastases, which are the primary reasons leading to patient mortality. In the present review, a number of pieces of evidence provide support for the potential uses of immunotherapy, including immunomodulation and vaccine therapy, for the eradication of tumors via upregulation of the immune response. Adoptive T-cell therapy and oncolytic virotherapy have been used to treat OS and resulted in objective responses. Immunologic checkpoint blockade and targeted therapy are also potentially promising therapeutic tools. Immunotherapy demonstrates significant promise with regard to improving the outcomes for patients exhibiting OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.